Senores Pharmaceuticals Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹5,617 Cr
- P/E
- 44.44
- ROE
- 13.42%
- PEG
- 0.30
- Price to sales
- 8.17
- Debt to equity
- 0.37
- 52W high / low
- ₹1,551 / ₹710
- EBITDA margin
- 29.23%
- Net profit margin
- 19.21%
- Promoter holding
- 45.81%
- Sales (last year)
- ₹688 Cr
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
Guidance scorecard · Q2 FY27 call
What Senores Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
40%+- Target revenue of INR 2,500 to 3,000 crores within 3-4 years.
- FY '27 guidance: 30%-40% revenue growth; 50%-60% PAT growth.
- Similar growth trajectory expected post FY '27, though exact FY '28 guidance is premature.
- Production capacity expansion at Apnar and US facilities to support growth.
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Senores Pharmaceuticals Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- FY27 Capex planned: INR 100-120 crores across subsidiaries, mainly for capacity expansion in oral solids and starting an injectable pilot plant.
- Apnar facility: Expanding with third and fourth production lines to ramp up oral solid manufacturing capacity.
- US plant capacities are also being increased to support regulated market growth.
- Sterile injectable project: Scaled down to a pilot facility with lower cost; full-scale execution pushed to H2 FY27 pending shareholder approval.
2 more points from Senores Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Senores Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Rising- Senores Pharmaceuticals has about 58 approved ANDAs, with 35 approved but yet to be launched.
- There are 39 more ANDAs (molecules) under development, some filed, some to be filed.
- The emerging markets segment has around 500 approved product registrations.
- Additionally, about 900 product registrations are currently in the pipeline, already filed with respective Ministries of Health.
2 more points from Senores Pharmaceuticals Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | Senores Pharmaceuticals LtdThis stock | 40%+ | Flat | ₹6,072 Cr | 48.0 |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Senores Pharmaceuticals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Senores Pharmaceuticals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Senores Pharmaceuticals Ltd
Shareholding breakup across reporting periods.
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters + | 45.77% | 45.78% | 45.78% | 45.80% | 45.81% | 45.82% | 45.82% | 45.81% |
| FIIs + | 4.25% | 4.17% | 3.66% | 4.28% | 3.35% | 3.64% | 6.62% | 6.01% |
| DIIs + | 11.77% | 9.66% | 9.51% | 8.62% | 9.32% | 9.62% | 9.77% | 10.85% |
| Public + | 38.20% | 40.39% | 41.03% | 41.30% | 41.54% | 40.92% | 37.78% | 37.32% |
| No. of Shareholders | 49,518 | 37,653 | 36,389 | 34,917 | 34,401 | 34,126 | 36,498 | 42,642 |
Financials of Senores Pharmaceuticals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 | 192 |
| Expenses + | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 | 135 |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 | 58 |
| OPM % | 19% | 22% | 27% | 23% | 25% | 17% | 25% | 31% | 29% | 27% | 30% | 30% |
| Other Income + | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 | 9 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 | 9 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 | 10 |
| Profit before tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 | 48 |
| Tax % | 31% | 19% | 19% | 18% | 20% | 13% | 20% | 26% | 25% | 23% | 23% | 23% |
| Net Profit + | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 | 37 |
| EPS in Rs | 2.37 | 5.23 | 3.23 | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 | 8.57 |
Financials of Senores Pharmaceuticals Ltd
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales + | 14 | 35 | 215 | 398 | 633 | 719 |
| Expenses + | 12 | 23 | 173 | 309 | 464 | 509 |
| Operating Profit | 2 | 13 | 42 | 90 | 168 | 209 |
| OPM % | 14% | 36% | 19% | 23% | 27% | 29% |
| Other Income + | 0 | 4 | 3 | 19 | 47 | 37 |
| Interest | 1 | 2 | 9 | 22 | 25 | 30 |
| Depreciation | 1 | 2 | 10 | 17 | 31 | 37 |
| Profit before tax | 1 | 12 | 25 | 71 | 159 | 179 |
| Tax % | 13% | 32% | -31% | 17% | 24% | |
| Net Profit + | 1 | 8 | 33 | 58 | 122 | 137 |
| EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 | 28.97 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Senores Pharmaceuticals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 888 | 957 |
| Borrowings + | 15 | 63 | 258 | 315 | 342 | 417 |
| Other Liabilities + | 8 | 23 | 160 | 126 | 328 | 261 |
| Total Liabilities | 59 | 131 | 622 | 1,227 | 1,604 | 1,681 |
| Fixed Assets + | 7 | 27 | 235 | 301 | 755 | 851 |
| CWIP | 8 | 34 | 97 | 172 | 17 | 31 |
| Investments | 15 | 16 | 0 | 0 | 4 | 6 |
| Other Assets + | 29 | 53 | 289 | 754 | 827 | 792 |
| Total Assets | 59 | 131 | 622 | 1,227 | 1,604 | 1,681 |
Financials of Senores Pharmaceuticals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | -10 | -1 | -26 | -46 | 62 |
| Cash from Investing Activity + | -24 | -48 | -54 | -429 | -121 |
| Cash from Financing Activity + | 36 | 46 | 87 | 573 | -1 |
| Net Cash Flow | 2 | -3 | 8 | 98 | -60 |
| Free Cash Flow | -21 | -48 | -78 | -203 | -203 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -526% | 3% | -56% | -41% | 45% |
Financials of Senores Pharmaceuticals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 506 | 228 | 191 | 114 | 187 |
| Inventory Days | 135 | 89 | 184 | 232 | 130 |
| Days Payable | 324 | 388 | 556 | 275 | 340 |
| Cash Conversion Cycle | 317 | -71 | -182 | 70 | -24 |
| Working Capital Days | 359 | -7 | -16 | 88 | 132 |
| ROCE % | 18% | 12% | 11% | 15% |
Guidance history
How Senores Pharmaceuticals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 40%+ | Flat | Planned | — | Rising |
| Q4 FY26 call → | 40%+ | Flat | Planned | Planned | Rising |
| Q3 FY26 call → | 20–40% | Flat | Planned | Planned | Rising |
| Q2 FY26 call → | 20–40% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
39 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +57.6% | 87% |
| Last 6 months | +35.6% | 83% |
| Last 3 months | −5.7% | 52% |
The price is 21.4% below its all-time high of ₹1,550.9 (19 Aug 2026). Stocks more than 20% below their peak have their score halved, so 78 became 39.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Senores Pharmaceuticals Ltd: 0.4 × 87 + 0.4 × 83 + 0.2 × 52 = 78, halved to 39 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY